Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases

Prostate cancer (PCa) is one of the most common types of malignancy, most patients with PCa will eventually progress to metastatic castration-resistant prostate cancer (mCRPC), which has a poor prognosis. Since 2004, chemotherapy has been approved by the FDA as the first-line treatment for mCRPC, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jian-zhou, Pan, Jin-feng, Ng, Derry Mingyao, Ying, Meng-qi, Jiang, Jun-hui, Ma, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071213/
https://www.ncbi.nlm.nih.gov/pubmed/33907422
http://dx.doi.org/10.2147/OTT.S297603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071213/
https://www.ncbi.nlm.nih.gov/pubmed/33907422
http://dx.doi.org/10.2147/OTT.S297603

Ejemplares similares